ESMO 2018 | The future therapeutic landscape of immunotherapy for mTNBC

Peter Schmid

Peter Schmid, MD, FRCP, PhD, of the Barts Cancer Institute, London, UK, speaks on his anticipation for results from the first clinical trials investigating the addition of immune checkpoint inhibitors to neoadjuvant preoperative chemotherapy in triple negative breast cancer (mTNBC). Prof. Schmid also discusses his expectations for immunotherapy-based clinical trials in mTNBC, and hopes more trials will further highlight the potential of paclitaxel and platinum-based therapies. This video was recorded at the European Society for Medical Oncology (ESMO) 2018 Congress, in Munich, Germany.

Share this video